title: 17beta-estradiol downregulates beta3-integrin expression in differentiating and mature human osteoclasts.
abstract: The increased bone resorption observed after estrogen withdrawal is responsible for bone loss and may lead to osteoporosis. The mechanism by which estradiol inhibits bone resorption is known to involve decreased osteoclastogenesis, however, the effect on osteoclast adhesion remains unclear. We examined the in vitro effect of estradiol and raloxifene on human osteoclast differentiation and function. Human peripheral blood mononuclear cells were cultured with M-CSF/RANK-L for 18 days, and we evaluated bone resorption, the expression of the protein and mRNA of the integrins, c-jun and c-fos in the presence or absence of estradiol. In this human model, beta3-integrin expression increased at the mRNA and protein levels during osteoclast differentiation, whereas that of beta5-integrin did not. We found that estradiol and raloxifene directly inhibited bone resorption on bone slices by 50%, and decreased the expression of beta3-integrin mRNA (60%) and protein (20%) in a time-dependent manner. Moreover, the mRNAs of c-fos and c-jun were both diminished by estradiol and raloxifene, particularly in early osteoclasts, but also to a lesser extent in mature cells. These findings suggest that the direct inhibitory action of estradiol on bone resorption may affect human osteoclast differentiation through downregulation of c-fos and c-jun and adhesion through modulation of beta3-integrin.
authors: Inserm U349, Hopital Lariboisiere, Paris, France.
authors: D
authors: D
authors: Saintier
authors: M-A
authors: MA
authors: Burde
authors: J M
authors: JM
authors: Rey
authors: T
authors: T
authors: Maudelonde
authors: M C
authors: MC
authors: de Vernejoul
authors: M E
authors: ME
authors: Cohen-Solal
mesh_terms: D015153:Blotting, Western; D001862:Bone Resorption / Q000378:metabolism*; D001842:Bone and Bones / Q000187:drug effects / Q000502:physiology; D002454:Cell Differentiation / Q000187:drug effects* / Q000502:physiology; D015536:Down-Regulation; D004958:Estradiol / Q000494:pharmacology*; D004965:Estrogen Antagonists / Q000494:pharmacology; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D039661:Integrin beta3 / Q000096:biosynthesis / Q000187:drug effects*; D009924:Organ Culture Techniques; D010010:Osteoclasts / Q000187:drug effects*; D016760:Proto-Oncogene Proteins c-fos / Q000187:drug effects / Q000502:physiology; D016755:Proto-Oncogene Proteins c-jun / Q000187:drug effects / Q000502:physiology; D012333:RNA, Messenger / Q000032:analysis; D020849:Raloxifene Hydrochloride / Q000494:pharmacology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors
chemical_list: D004965:Estrogen Antagonists; D039661:Integrin beta3; D016760:Proto-Oncogene Proteins c-fos; D016755:Proto-Oncogene Proteins c-jun; D012333:RNA, Messenger; D020849:Raloxifene Hydrochloride; D004958:Estradiol